Peptide Library
Searchable, scored, and cited. Every peptide page pulls live data from institutional sources (FDA, NIH, EMBL-EBI). Browse by goal below or filter by evidence quality.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
Retatrutide
Fat LossEli Lilly's triple agonist (GLP-1 / GIP / glucagon receptor). Currently the most potent weight-management investigational drug — Phase 2 trials reported ~24% body weight reduction at the highest dose. Phase 3 TRIUMPH program ongoing. Not yet FDA-approved.
Orforglipron
Fat LossEli Lilly's once-daily ORAL non-peptide GLP-1 receptor agonist (LY3502970). The first oral small-molecule GLP-1 with no food/water restrictions (unlike Rybelsus). Phase 3 ACHIEVE program for diabetes and ATTAIN for obesity both ongoing.
CJC-1295 / Ipamorelin
MuscleGrowth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.